Sanofi (SNY -2%) and Regeneron (REGN -2.5%) today announce that they are enrolling patients in more than 10 late-stage clinical trials , named Odyssey, for a potentially first-in-class cholesterol - lowering drug targeting an enzyme called PCSK9. Odyssey will involve more than 22K patients, including 18K in a trial to measure cardiovascular outcomes such as heart attacks and strokes.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at MarketWatch.com (Feb 19, 2015)
at Benzinga.com (Feb 5, 2015)
at Benzinga.com (Jan 15, 2015)
at CNBC.com (Jan 9, 2015)
at Investor's Business Daily (Jan 8, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs